What oral anti‑androgen alternatives to spironolactone can be used for treating hirsutism and acne in women of child‑bearing age?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Oral Anti-Androgen Alternatives to Spironolactone for Hirsutism and Acne

For women of childbearing age with hirsutism and acne, oral contraceptives (OCPs) are the recommended first-line treatment, with cyproterone acetate (CPA) 2 mg combined with ethinyl estradiol being particularly effective; finasteride 5 mg daily can serve as an alternative antiandrogen, while flutamide should be avoided due to hepatotoxicity risk. 1

Primary Alternative: Oral Contraceptives

The Endocrine Society guidelines clearly prioritize OCPs as first-line therapy for the majority of women with hirsutism 1. This recommendation is based on:

  • Efficacy: OCPs reduce free testosterone by increasing sex hormone-binding globulin (SHBG) and suppressing ovarian androgen production
  • Safety profile: Similar side effects to placebo in clinical trials
  • Dual benefit: Provides contraception while treating hyperandrogenic symptoms

Specific OCP Formulations

OCPs containing antiandrogen progestins are most effective:

  • Cyproterone acetate (CPA) 2 mg + ethinyl estradiol: Most effective option, showing similar efficacy to other antiandrogens in systematic reviews 1. CPA blocks androgen receptors and inhibits 5α-reductase activity. Note: CPA is not available in the United States.

  • Drospirenone 3 mg + ethinyl estradiol: FDA-approved for acne in patients ≥14 years 2. However, drospirenone is a weak antiandrogen (3 mg drospirenone ≈ 25 mg spironolactone) 1. A 12-month trial showed similar hirsutism reduction compared to CPA 1.

  • Other progestins: Dienogest, desogestrel, and chlormadinone acetate have demonstrated antiacne activity 3, though research suggests dienogest may not impact hirsutism 4.

Secondary Alternative: Finasteride

Finasteride 5 mg daily is a reasonable alternative antiandrogen when OCPs are contraindicated or not tolerated 1:

  • Mechanism: Inhibits type 2 5α-reductase, reducing conversion of testosterone to dihydrotestosterone (DHT)
  • Efficacy: Reduces hirsutism scores by 30-60% 1. Meta-analysis showed no significant differences between finasteride, spironolactone, and flutamide versus placebo 1
  • Comparative data: One trial suggested equal efficacy to spironolactone 100 mg, though another found spironolactone more effective with prolonged treatment 1
  • Safety: No major adverse effects reported 1
  • Dosing: 5 mg daily is standard, though some data suggest 2.5 mg and 5 mg are equally effective 1

Critical caveat: Finasteride is teratogenic and requires strict contraception 1. The guidelines explicitly recommend against antiandrogen monotherapy unless adequate contraception is used 1.

Alternatives to AVOID

Flutamide: Not Recommended

The guidelines explicitly recommend against flutamide therapy 1 despite its efficacy:

  • Efficacy: Doses of 250-750 mg/day show similar efficacy to spironolactone 100 mg/day 1
  • Major concern: Hepatotoxicity leading to liver failure and death 1
  • Risk mitigation: Hepatotoxicity may be dose-related; lower doses (62.5-375 mg/day) showed no hepatotoxicity in some series 1
  • Guideline position: Not first-line therapy; if used, employ lowest effective dose with close monitoring 1

Other Non-Recommended Options

  • Topical antiandrogens: Limited efficacy, not recommended 1
  • Insulin-lowering drugs (metformin, thiazolidinediones): Not recommended for hirsutism treatment 1
  • GnRH agonists: Reserved only for severe hyperandrogenemia (e.g., ovarian hyperthecosis) with suboptimal response to OCPs and antiandrogens 1
  • Glucocorticoids: Only for nonclassic congenital adrenal hyperplasia with suboptimal response to first-line therapies 1

Treatment Algorithm

For women of childbearing age:

  1. First-line: Start OCP (preferably CPA-containing if available, or drospirenone-containing)
  2. Trial duration: Minimum 6 months before changing therapy 1
  3. If inadequate response after 6 months: Add antiandrogen to OCP 1
  4. If OCPs contraindicated/not tolerated: Finasteride 5 mg daily with mandatory contraception
  5. Avoid: Flutamide as routine therapy

For women who cannot or choose not to conceive: Either OCPs or antiandrogens (finasteride preferred over flutamide), with choice based on patient preferences regarding efficacy, side effects, and costs 1.

Important Clinical Considerations

  • Contraception is mandatory with all antiandrogen monotherapy due to teratogenic potential 1, 5
  • Treatment duration: All pharmacological therapies require at least 6 months before assessing response 1
  • Combination therapy: If monotherapy with OCP fails after 6 months, add an antiandrogen rather than switching 1
  • Patient counseling: Discuss realistic expectations, as improvement is gradual and requires sustained therapy

References

Guideline

guidelines of care for the management of acne vulgaris.

Journal of the American Academy of Dermatology, 2024

Research

[Hormonal antiandrogens in acne treatment].

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.